Drug ApprovalsFDA approves immunotherapy that can spare rectal cancer surgery
Jemperli won accelerated approval for dMMR or MSI-H stage II and III rectal cancer after most AZUR-1 patients needed no chemotherapy, radiotherapy or surgery.
19 October 2026